H1 Raises $40M from CVS Health Ventures
SkimNews Take
H1's success demonstrates that established corporations are actively seeking to integrate specialized data platforms, even as venture capital prioritizes generative AI, suggesting a bifurcated investment landscape.
Get the Tech newsletter
Daily tech — startups, AI labs, chips, the launches that shape the next decade. Free.
- H1 secured a $40 million investment led by CVS Health Ventures, the corporate VC arm of CVS/Aetna.
- H1 reported cash‑flow positive and EBITDA profitability in the prior year and projects over 40 % revenue growth for the current year.
- H1 was valued at $750 million after a $100 million round led by Altimeter Capital in November 2021.
- Ariel Katz (CEO of H1) said the company’s physician‑data platform is not easily replicated by AI models such as Anthropic’s Claude and may become a customer for AI developers.
- H1 has pursued growth through acquisitions of smaller competitors and complementary businesses.
Why it matters: CVS Health gains a strategic data partner to enhance its pharma and insurer services, while H1 secures growth capital without diluting ownership; the deal shows data‑centric SaaS can thrive even as VC focus shifts to AI.
